Key facts
- This page summarizes Brendan Teehan's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 19 Nov 2024, 20:43.
Brendan Teehan - 17 Nov 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)
- Reporting relationship
- EVP, COO, HEAD OF COMMERCIAL
- Issuer ticker
- ACAD
- Reported as of
- 17 Nov 2024
- Net transaction value
- -$173,630
- SEC form
- 4
- Accepted by SEC
- 19 Nov 2024, 20:43:42 UTC
- Prior SEC filing
- 20 Aug 2024
- Next SEC filing
- 28 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer J. Rhodes, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brendan Teehan filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 19 Nov 2024.
Change
- Previous filing in this sequence was filed on 20 Aug 2024.
- Current net transaction value: -$173,630.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACAD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +9,913
- Change %
- +19%
- Price
- Shares after
- 62,521
- Date
- 17 Nov 2024
- Ownership
- Direct
- Footnotes
- F1, F2
ACAD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +9,913
- Change %
- +16%
- Price
- Shares after
- 72,434
- Date
- 17 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
ACAD
transaction
Common Stock
Sale
- Transaction value
- $173,630
- Shares
- -10,329
- Change %
- -14%
- Price
- $16.81
- Shares after
- 62,105
- Date
- 19 Nov 2024
- Ownership
- Direct
- Footnotes
- F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACAD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -9,913
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 9,913
- Date
- 17 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,913
- Exercise price
- Footnotes
- F1, F5
ACAD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -9,913
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 9,913
- Date
- 17 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,913
- Exercise price
- Footnotes
- F1, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Brendan Teehan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 6 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
Includes 431 shares of the Issuer's common stock acquired by the reporting person on November 15, 2024 pursuant to an employee stock purchase plan.
Footnote F3
The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.7947 to $16.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F5
The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
Footnote F6
The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.